Tumor Susceptibility Gene 101 (TSG101) (Middle Region) Peptid
TSG101
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN5514362
Kurzübersicht für Tumor Susceptibility Gene 101 (TSG101) (Middle Region) Peptid (ABIN5514362)
Target
TSG101
(Tumor Susceptibility Gene 101 (TSG101))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Sequenz
- TGPPNTSYMP GMPGGISPYP SGYPPNPSGY PGCPYPPGGP YPATTSSQYP
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-TS101 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- TSG101 (Tumor Susceptibility Gene 101 (TSG101))
-
Hintergrund
-
The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.
Alias Symbols: TSG101,
Protein Size: 285 -
Gen-ID
- 7251
Target
-
Sie sind hier:
